Denis Corin, president of TapImmune, said: “We are proud to team with Aeras in the search for the next generation of vaccines to eliminate the scourge of tuberculosis from the world. We are equally proud that our technology has been recognized as a potential meaningful contributor in that search.”
Aeras, a non-profit Product Development Partnerships, is dedicated to the development of effective TB vaccine regimens to prevent tuberculosis in all age groups, and will be affordable, available and adopted worldwide.
TapImmune has extensive experience and associated intellectual property related to the use of TAP1 and TAP2 expressing vectors for the treatment of cancer, and also as molecular adjuvants for enhancing Class I presentation of vaccine immunogens.